Atypical hemolytic uremic syndrome: Update on the complement system and what is new

Nephron - Clinical Practice

Volumn 114, Issue 4, 2010, Pages

  Hirt Minkowski, Patricia ^a   Dickenmann, Michael ^a   Schifferli, Jürg A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Complement C3; Complement factor H; Complement system; Factor B; Factor I; Hemolytic uremic syndrome; Membrane cofactor protein (CD46); Plasma therapy; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIBODY; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H ANTIBODY; COMPLEMENT FACTOR I; ECULIZUMAB; FRESH FROZEN PLASMA; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE COFACTOR PROTEIN; OCTAPLAS; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

CELL PROTECTION; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT FACTOR H DEFICIENCY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DISEASE COURSE; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MORTALITY; NONHUMAN; ONSET AGE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RISK; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHORT SURVEY; STEROID THERAPY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PLASMA EXCHANGE; STEM CELL TRANSPLANTATION;

EID: 74249113609     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276545     Document Type: Short Survey

References (84)

1. Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23: 1749-1760.
2. Neumann HPH, Zipfel PF: Hämolytischurämisches Syndrom im Erwachsenenalter. Spektrum Nephrol 2007; 1: 15-24.
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B: Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584. (Pubitemid 28536132)
4. Tsai HM, Lian ECY: Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594. (Pubitemid 28536133)
5. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494. (Pubitemid 32938741)
6. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B: Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713. (Pubitemid 34761143)
7. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE: ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68. (Pubitemid 36759636)
8. Dragon-Durey MA, Frémeaux-Bacchi V: Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 2005; 27: 359-374. (Pubitemid 41639887)
9. Caprioli J, Peng L, Remuzzi G: The hemolytic uremic syndromes. Curr Opin Crit Care 2005; 11: 487-492. (Pubitemid 41482706)
10. Fakhouri F, Frémeaux-Bacchi V: Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007; 3: 679-687. (Pubitemid 350146966)
11. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, European Paediatric Research Group for HUS: A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431.
12. Walport MJ: Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
13. Kohl J: Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38: 175-187. (Pubitemid 32786775)
14. Schraufstatter lU, Trieu K, Sikora L, Sriramarao P, DiScipio R: Complement C3a and C5a induce different signal transduction cascades in endothelial cells. J Immunol 2002; 169: 2102-2110. (Pubitemid 34857676)
15. Watanabe H, Kuraya M, Kasukawa R, Yanagisawa H, Yanagisawa M, Fujita T: Analysis of C5a receptor by monoclonal antibody. J Immunol Methods 1995; 185: 19-29.
16. Wiedmer T, Sims PJ: Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood 1991; 78: 2880-2886.
17. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ: C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol 2000; 278:F747-F757. (Pubitemid 30351076)
18. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ: A new model of renal microvascular endothelial injury. Kidney Int 1997; 52: 182-194. (Pubitemid 27321829)
19. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Johnson RJ, Couser WG: Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int 1997; 52: 1570-1578. (Pubitemid 28032060)
20. Thompson RA, Winterborn MH: Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46: 110-119.
21. Warwicker P, Goodship THJ, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844. (Pubitemid 28155655)
22. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279. (Pubitemid 44232024)
23. Frémeaux-Bacchi V, Kemp EJ, Goodship THJ, Dragon-Durey MA, Strain L, Loirat C, Deng HW, Goodship JA: The development of atypical HUS is influenced by susceptibility factors in factor H and membrane cofactor protein - evidence from two independent cohorts. J Med Genet 2005; 42: 852-856. (Pubitemid 41598193)
24. Sellier-Leclerc AL, Frémeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C: Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400. (Pubitemid 47203855)
25. Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Frémeaux-Bacchi V, Skerka CH, Zipfel PF, Goodship THJ, Noris M, Remuzzi G, Rodriguez de Cordoba S, European Working Party on the Genetics of HUS: The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008; 19: 639-646.
26. Neumann HPH, Salzmann M, Bohnert- Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF: Haemolytic uraemic syndrome and mutations of the factor H gene: a registry based study of Germanspeaking countries. J Med Genet 2003; 40: 676-681. (Pubitemid 37100700)
27. Goicoechea de Jorge E, Harris CL, Esparza- Gordillo J, Carreras L, Aller Arranz E, Abarrategui Garrido C, López-Trascasa M, Sánchez- Corral P, Morgan BP, de Cordoba SR: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104: 240-245. (Pubitemid 46068016)
28. Frémeaux-Bacchi V, Regnier CH, Dragon- Durey MA, Janssen B, Atkinson J: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2007; 112: 4948-4952. (Pubitemid 47203855)
29. Ripoche J, Day AJ, Harris TJ, Sim RB: The complete amino acid sequence of human complement factor H. Biochem J 1988; 249: 593-602. (Pubitemid 18030952)
30. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P: The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-367. (Pubitemid 38639887)
31. Kuhn S, Skerka C, Zipfel PF: Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol 1995; 155: 5663-5670.
32. Zipfel PF, Skerka C: Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today 1994; 15: 121-126. (Pubitemid 24076329)
33. Rodriguez de Cordoba S, Lublin DM, Rubinstein P, Atkinson JP: Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med 1985; 161: 1189-1195. (Pubitemid 15011333)
34. Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship THJ, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ: The interactive factor Hatypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat 2007; 28: 222-234. (Pubitemid 46309972)
35. Pickering MC, Cook HT: Translational minireview series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008; 151: 210-230.
36. Atkinson JP, Liszewski MK, Richards A, Kavanagh D, Moulton EA: Hemolytic uremic syndrome. An example of insufficient complement regulation on self-tissue. Ann NY Acad Sci 2005; 1056: 144-152. (Pubitemid 43030973)
37. Montes T, Goicoechea de Jorge E, Ramos R, Gomà M, Pujol O, Sánchez-Corral P, Rodriguez de Cordoba S: Genetic deficiency of complement factor H in a patient with agerelated macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 2008; 45: 2897-2904.
38. Rodriguez de Cordoba S, Goicoechea de Jorge E: Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151: 1-13. (Pubitemid 350230999)
39. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN, Manchester M, Atkinson JP: Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 2000; 275: 37692-37701. (Pubitemid 32004883)
40. Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP: CD46: expanding beyond complement regulation. Trends Immunol 2004; 25: 496-503. (Pubitemid 39490257)
41. Richards A, Kemp EJ, Liszewski MK, Goodship THJ, Lampe AK, Decorte R, Müslümanoǧlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship JA: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003; 100: 12966-12971. (Pubitemid 37340009)
42. Frémeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH: Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41:E84.
43. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship THJ: Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 2150-2155. (Pubitemid 41716447)
44. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International Registry of Recurrent and Familial HUS/TTP: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-3395. (Pubitemid 37541083)
45. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Berges LC, López-Trascasa M, Sánchez- Corral P, Rodriguez de Córdoba S: Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712. (Pubitemid 40309595)
46. Pickering MC, Goicoechea de Jorge E, Martinez- Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, Rodriguez de Córdoba S, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249-1256. (Pubitemid 46919861)
47. Frémeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, Deng HW, Goodship THJ: The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005; 42: 852-856. (Pubitemid 41598193)
48. Esparza-Gordillo J, Goicoechea de Jorge E, Abarrategui Garrido C, Carreras L, López- Trascasa M, Sánchez-Corral P, Rodriguez de Córdoba S: Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006; 43: 1769-1775.
49. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V: Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563. (Pubitemid 41725154)
50. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF: Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110: 1516-1518. (Pubitemid 47443967)
51. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C: Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514. (Pubitemid 351213440)
52. Fang CJ, Frémeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship THJ, Atkinson JP: Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis and the HELLP syndrome. Blood 2007; 111: 624-632. (Pubitemid 44754841)
53. Edey MM, Mead PA, Saunders RE, Strain L, Perkins SJ, Goodship THJ, Kanagasundaram NS: Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis 2008; 51: 487-490. (Pubitemid 351273479)
54. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035-1050. (Pubitemid 41710314)
55. Eriksson KJ, Boyd SG, Tasker RC: Acute neurology and neurophysiology of haemolyticuraemic syndrome. Arch Dis Child 2001; 84: 434-435.
56. Larakeb A, Leroy S, Frémeaux-Bacchi V, Montchilova M, Pelosse B, Dunand O, Deschênes G, Bensman A, Ulinski T: Ocular involvement in hemolytic uremic syndrome due to factor H deficiency - are there therapeutic consequences? Pediatr Nephrol 2007; 22: 1967-1970. (Pubitemid 47506240)
57. Sturm V, Menke MN, Landau K, Laube GF, Neuhaus TJ: Ocular involvement in paediatric haemolytic uraemic syndrome. Acta Ophthalmol 2009, E-pub ahead of print.
58. Argyle JG, Hogg RJ, Ryslier TJ, Silva FG, Siegler RL: A clinicopathological study of 24 children with hemolytic uremic syndrome. Pediatr Nephrol 1990; 4: 52-58.
59. Bonser RS, Adu D, Franklin I, McMaster P: Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984; 2: 1337. (Pubitemid 15176818)
60. Moake JL, Byrnes JJ: Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am 1996; 10: 485-497. (Pubitemid 26097348)
61. Abraham KA, Little MA, Dorman AM, Walshe JJ: Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000; 13: 443-447.
62. Hogan MC, Gloor JM, Uhl JR, Cockerill FR, Milliner DS: Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection. Am J Kidney Dis 2001; 38:E22.
63. Kavanagh D, Richards A, Frémeaux-Bacchi V, Noris M, Goodship THJ, Remuzzi G, Atkinson JP: Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007; 2: 591-596. (Pubitemid 47203855)
64. Ariceta G, Besbas N, Johnson S. Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor C, Van De Kar N, Van De Walle J, Zimmerhackl L: Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.
65. Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH: Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis 2006; 47:e27-e30. (Pubitemid 43121349)
66. Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, Frémeaux-Bacci V, Loirat C: Successful pretransplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008; 23: 2088-2090. (Pubitemid 351768178)
67. Amara U, Rittirsch D, Flierl M, Brückner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M: Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632: 71-79.
68. Loirat C, Frémeaux-Bacci V: Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12: 619-629.
69. Loirat C, Niaudet P: The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18: 1095-1101. (Pubitemid 37406854)
70. Frémeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N. Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP: Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025. (Pubitemid 44036186)
71. Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A: Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 2007; 7: 2047-2051. (Pubitemid 47037998)
72. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J: Hemolytic uremic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009; 24: 3548-3551.
73. Donne RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship THJ: Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002; 40:e22.
74. Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group: Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008; 20: 940-949.
75. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M: Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006; 103: 9649-9654. (Pubitemid 43955879)
76. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP: Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559. (Pubitemid 38160785)
77. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 335: 1233-1243. (Pubitemid 44427447)
78. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P: Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840-1847. (Pubitemid 351451491)
79. Gruppo RA: Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546.
80. Nürnberger J, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M: Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.
81. Symmers WSC: Thrombotic microangiopathic haemolytic anemia (thrombotic microangiopathy). Br Med J 1952;2:897-903.
82. Moschcowitz E: An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Proc NY Pathol Soc 1924;21- 24.
83. Reprinted in Mt Sinai J Med 2003;70:322-325.
84. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R: Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia (in German). Schweiz Med Wochenschr 1955;85: 905-909.